Zyfis Lifesciences Pvt. Ltd.’s Post

Hepatitis B is a significant global health issue affecting millions, which leads to serious complications like liver cirrhosis and cancer. Preventing mother-to-child Hepatitis B transmission is essential to safeguarding future generations and advancing global health equity. Preventive measures such as vaccination, safe practices, and early detection are crucial to reducing the burden on individuals and healthcare systems. By focusing on prevention, we can save lives, improve quality of life, and reduce healthcare costs. Using an interdisciplinary approach is vital to effectively combatting Hepatitis B. This strategy leverages the expertise and perspectives of various fields, ensuring a holistic intervention. Follow Strong Girls Evolution's Facebook page and join us on Saturday for this impactful interdisciplinary dialogue in Krio. #globalhealthequity #healthsystems #maternalhealth #childhealth #hepatitis

Sunday is National Herpes Awareness Day in the US and a crucial reminder of the importance of education, awareness, and access to treatment for herpes infections. While herpes can often be managed in immunocompetent individuals, we must not overlook those who face greater challenges—such as individuals undergoing medical treatments that suppress their immune systems or those with immunodeficiencies. It is essential that research into new treatments for drug-resistant strains takes into account the serious impact this virus can have on overall health and well-being.    AiCuris is currently advancing pritelivir, a treatment for acyclovir-resistant HSV, in a pivotal Phase 3 study, providing hope for those with limited therapeutic options.    Visit https://lnkd.in/g-PPGtDG to learn more about how you can support current advocacy efforts.     #HerpesAwareness #HealthcareInnovation #HSV #InfectionTreatment #ClinicalTrials 

🌍 Today, on World Pneumonia Day 2024, let's unite to protect lives against one of the most devastating – yet preventable – diseases. 🌍 Pneumonia claims the lives of over 700,000 children under the age of five each year and remains a top cause of death among older adults and immunocompromised individuals globally. This disease often strikes the most vulnerable communities, where access to healthcare, vaccines, and early diagnosis is limited. 🔹 Why should we care? Pneumonia is preventable and treatable. With timely vaccines, better access to healthcare, and supportive interventions, we can prevent thousands of deaths every year. However, the battle against pneumonia requires global attention, funding, and policy changes to make healthcare more equitable and accessible. 🔹 How can we make a difference? To protect lives, we must raise awareness, support vaccine distribution, and strengthen healthcare systems worldwide. By sharing knowledge and resources, advocating for policies, and supporting organizations working tirelessly to end pneumonia, we can collectively work towards reducing the impact of this disease on families and communities. 🔹 Join the movement: Visit https://lnkd.in/djuNzAJk Stop Pneumonia to learn how you can be part of the solution. Every voice and action counts in the fight for a healthier world. Together, let's work towards a future where everyone – regardless of their age, location, or background – can live without the fear of pneumonia. 💙 #WorldPneumoniaDay #StopPneumonia #GlobalHealth #HealthForAll #EndPneumonia #PublicHealth

With countless health prevention strategies available — from cancer screenings to vaccines — knowing which ones to prioritize for your age group is vital. Check out this guide from UCLA Health to take charge of your preventive health today: https://lnkd.in/diCKUt_T  

#RSV is the world's top cause of severe respiratory infections and hospitalization in young children—responsible for 1 in every 28 deaths occurring before six months of age. A new maternal vaccine and long-acting monoclonal antibody could help change that! Experts—including PATH's Clint Pecenka, Ranju Baral, and Jessica Fleming—explain in The Lancet. Every country should have the opportunity to choose which product best fits the needs of its population and its health system. That’s why ensuring that these products can be available, affordable, and accessible is so important, especially for countries with low- and middle-income economies where nearly all RSV deaths occur. Read the article to learn about the new RSV interventions and the challenges and opportunities on the road to their global authorization and implementation. Also included are spotlights from Argentina, Kenya, and Spain that bring different contexts and perspectives to life. https://lnkd.in/exTJpAmZ

📈 Non-communicable diseases (NCDs) cause 74% of deaths globally – that’s 41 million deaths every year and rising! ⏲️ Acting early on NCDs through screening and early detection is key to reducing the burden of these diseases. 🌍 This approach will provide benefits for all – improving health outcomes for people, reducing pressures on health systems, and benefitting society by boosting economic activity and workforce participation. To learn more about the action needed to address NCDs and how @AstraZeneca is helping to drive change, read this article by Iskra Reic, Executive Vice President, Vaccines & Immune Therapies: https://lnkd.in/gpvxFz2V #WHS2024 #NCDs #Interconnectedhealth

In this study, experts, including PATH explore the regulatory, policy, implementation pathways and intervention uptake of RSV vaccines and monoclonal antibodies in Spain and Argentina including in Kenya.   Beyond this, PATH and WHO are engaged through the Advancing Maternal Immunization (AMI) collaboration to develop a more detailed gap analysis describing the evidence, information, and policy needs of global and country decision-makers, public health program planners and implementers involved in decision-making and introducing maternal RSV vaccines. PATH's RSV and mAb Trial Tracker: https://lnkd.in/eJC7GpXG

📈 Non-communicable diseases (NCDs) cause 74% of deaths globally – that’s 41 million deaths every year and rising! ⏲️ Acting early on NCDs through screening and early detection is key to reducing the burden of these diseases. 🌍 This approach will provide benefits for all – improving health outcomes for people, reducing pressures on health systems, and benefitting society by boosting economic activity and workforce participation. To learn more about the action needed to address NCDs and how AstraZeneca is helping to drive change, please consider reading this short article by Iskra Reic, Executive Vice President, Vaccines & Immune Therapies: https://lnkd.in/ebfRs6DE #WHS2024 #NCDs #Interconnectedhealth

Staying up to date with the latest clinical guidance is vital for delivering the best patient care. At Best Practice London 2025, we’ll cover the key updates shaping primary care, including: • New guidance for asthma and non-alcoholic fatty liver disease (NAFLD) • Updates to the new vaccination schedule • Emerging therapy options, such as advancements in lipid management Join us for practical sessions designed to help you translate these updates into meaningful improvements in your daily practice. Register for free today 👇 https://lnkd.in/ehJ82xbj #BestPracticeShow #BestPracticeLondon #ClinicalUpdates #PrimaryCare #GeneralPractice #HealthcareInnovation

We're expanding our program offering subsidized COVID-19 and flu vaccine clinics to all licensed long-term care facility residents and staff who might not otherwise have access! Communicable diseases such as COVID-19 and the flu can spread quickly in congregate living settings. In addition, they can lead to potential staffing shortages. To date, we've coordinated seven clinics, and 24 are in progress. Read more in this news release: https://lnkd.in/gTjUP3Tk